Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The Prevention of Medication-related Osteonecrosis of the Jaw.

Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P.

Dtsch Arztebl Int. 2017 Feb 3;114(5):63-69. doi: 10.3238/arztebl.2017.0063.

2.

Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.

Gu T, Eisenberg Lawrence DF, Stephenson JJ, Yu J.

Clin Interv Aging. 2016 Feb 15;11:1-8. doi: 10.2147/CIA.S97593. eCollection 2016.

3.

Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.

Villa JC, Gianakos A, Lane JM.

HSS J. 2016 Feb;12(1):66-73. doi: 10.1007/s11420-015-9469-1. Epub 2015 Dec 9. Review.

4.

Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational Studies.

Teng S, Yi C, Krettek C, Jagodzinski M.

PLoS One. 2015 Oct 7;10(10):e0139927. doi: 10.1371/journal.pone.0139927. eCollection 2015.

5.

The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink.

Ferguson S, Feudjo Tepie M, Taylor A, Roddam A, Critchlow C, Iqbal M, Spangler L, Bayly J.

J Eval Clin Pract. 2016 Feb;22(1):31-39. doi: 10.1111/jep.12422. Epub 2015 Aug 16.

6.

Bisphosphonate drug holidays: Can we recommend currently?

Tandon VR, Sharma S, Mahajan A.

J Midlife Health. 2014 Jul;5(3):111-4. doi: 10.4103/0976-7800.141186. Review.

7.

Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.

Magaziner JS, Orwig DL, Lyles KW, Nordsletten L, Boonen S, Adachi JD, Recknor C, Colón-Emeric CS, Mesenbrink P, Bucci-Rechtweg C, Su G, Johnson R, Pieper CF.

J Bone Miner Res. 2014 Dec;29(12):2545-51. doi: 10.1002/jbmr.2283.

8.

Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.

Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J.

Can Fam Physician. 2014 Apr;60(4):324-33. Review.

9.

Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women.

Balasubramanian A, Brookhart MA, Goli V, Critchlow CW.

Int J Gen Med. 2013 Nov 6;6:839-48. doi: 10.2147/IJGM.S36944. eCollection 2013.

10.
11.

Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.

Gates BJ, Das S.

Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:1-14. doi: 10.4137/CMAMD.S4092. Epub 2012 Jan 5.

12.

Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study.

Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C, Arden NK.

BMJ. 2011 Dec 6;343:d7222. doi: 10.1136/bmj.d7222.

13.

Long-term safety concerns of antiresorptive therapy.

Zhang J, Saag KG, Curtis JR.

Rheum Dis Clin North Am. 2011 Aug;37(3):387-400, vi. doi: 10.1016/j.rdc.2011.08.001. Review.

14.
15.

Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.

Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM.

Osteoporos Int. 2012 Mar;23(3):1075-82. doi: 10.1007/s00198-011-1645-7. Epub 2011 May 21.

16.

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.

Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):967-82. doi: 10.1007/s00198-010-1424-x. Epub 2010 Oct 9.

17.

Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.

Netelenbos JC, Geusens PP, Ypma G, Buijs SJ.

Osteoporos Int. 2011 May;22(5):1537-46. doi: 10.1007/s00198-010-1372-5. Epub 2010 Sep 14.

18.

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Isaacs JD, Shidiak L, Harris IA, Szomor ZL.

Clin Orthop Relat Res. 2010 Dec;468(12):3384-92. doi: 10.1007/s11999-010-1535-x. Epub 2010 Aug 31.

20.

Measuring and improving adherence to osteoporosis pharmacotherapy.

Cadarette SM, Burden AM.

Curr Opin Rheumatol. 2010 Jul;22(4):397-403. doi: 10.1097/BOR.0b013e32833ac7fe. Review.

Supplemental Content

Support Center